These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37782096)

  • 21. Adverse event following vaccine surveillance in Kaduna State, Northwestern Nigeria (January 2018 -June 2019): analysis of health facility´s records.
    Ishaku SG; Umeh G; Adzu B; Onimisi A; Dauda M; Iyal HA; Iliyasu N; Sunday DJ; Daikwo J; Yates SM; Ibrahim II; Samaila LH; Abdullahi B; Parom SK; Maiwashi KY; Zakari F; Nuhu KS
    Pan Afr Med J; 2021; 40():268. PubMed ID: 35251462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Barriers to healthcare workers reporting adverse events following immunization in Zhejiang province, China.
    Lv H; Pan X; Wang Y; Liang H; Yu H
    Hum Vaccin Immunother; 2022 Nov; 18(5):2083865. PubMed ID: 35820038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of a new global indicator for vaccine safety surveillance and trends in adverse events following immunization reporting 2000-2015.
    Lei J; Balakrishnan MR; Gidudu JF; Zuber PLF
    Vaccine; 2018 Mar; 36(12):1577-1582. PubMed ID: 29454518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adverse event following immunization (AEFI) surveillance in India, position paper of Indian Academy of Pediatrics,2013.
    Chitkara AJ; Thacker N; Vashishtha VM; Bansal CP; Gupta SG
    Indian Pediatr; 2013 Aug; 50(8):739-41. PubMed ID: 24036641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A scoping review of active, participant-centred, digital adverse events following immunization (AEFI) surveillance: A Canadian immunization research network study.
    Psihogios A; Brianne Bota A; Mithani SS; Greyson D; Zhu DT; Fung SG; Wilson SE; Fell DB; Top KA; Bettinger JA; Wilson K
    Vaccine; 2022 Jul; 40(31):4065-4080. PubMed ID: 35680501
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine using the national adverse event following immunization surveillance system from Zhejiang province, 2018-2020.
    Hu Y; Pan X; Shen L; Chen F; Wang Y; Liang H; Chen Y; Lv H
    Hum Vaccin Immunother; 2021 Dec; 17(12):5447-5453. PubMed ID: 34613883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An evaluation of adverse events following an immunization campaign with the live, attenuated SA14-14-2 Japanese encephalitis vaccine in Cambodia.
    Hills SL; Soeung SC; Sarath S; Morn C; Dara C; Fischer M; Thigpen MC
    PLoS One; 2022; 17(6):e0269480. PubMed ID: 35679297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surveillance of adverse events following immunization in Oman, 2006-2015.
    Patel PK; Al-Rawahi B; Al-Jawari A; Al-Abaidani I; Al-Abri S
    East Mediterr Health J; 2018 May; 24(2):119-126. PubMed ID: 29748940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surveillance of adverse events following immunisation: Australia 2002 to 2003.
    Lawrence G; Boyd I; McIntyre P; Isaacs D
    Commun Dis Intell Q Rep; 2004; 28(3):324-38. PubMed ID: 15574056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Routine surveillance of adverse events following immunization as an important tool to monitor vaccine safety.
    Alicino C; Merlano C; Zappettini S; Schiaffino S; Della Luna G; Accardo C; Gasparini R; Durando P; Icardi G
    Hum Vaccin Immunother; 2015; 11(1):91-4. PubMed ID: 25483520
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse events following immunization: real causality and myths.
    Principi N; Esposito S
    Expert Opin Drug Saf; 2016 Jun; 15(6):825-35. PubMed ID: 26986067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surveillance of adverse events following immunisation: Australia, 2000-2002.
    Lawrence G; Menzies R; Burgess M; McIntyre P; Wood N; Boyd I; Purcell P; Isaacs D
    Commun Dis Intell Q Rep; 2003; 27(3):307-23. PubMed ID: 14510057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lessons on causality assessment and communications from the 2019 South-East Asia Regional (SEAR) workshop on inter-country expert review of selected Adverse Events Following Immunization (AEFI) cases.
    MacDonald NE; Guichard S; Arora N; Menning L; Wilhelm E;
    Vaccine; 2020 Jul; 38(32):4924-4932. PubMed ID: 31611095
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Active surveillance of adverse events after immunization (AEFI) from the Local Health Unitof Ferrara, Italy.
    Marra A; Donzelli A; Florescu C; Rauzino A; Mattei A; Sbarbati MM; Fiasca F; Stefanati A; Gabutti G
    J Prev Med Hyg; 2022 Jun; 63(2):E208-E212. PubMed ID: 35968066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and feasibility of SMS m-Health for the detection of adverse events following immunisation (AEFIs) in resource-limited setting-The Zimbabwe stimulated telephone assisted rapid safety surveillance (Zm-STARSS) randomised control trial.
    Nyambayo PPM; Gold MS; Mehta UC; Clarke S; Manyevere R; Chirinda L; Zifamba EN; Nyamandi T
    Vaccine; 2023 Oct; 41(45):6700-6709. PubMed ID: 37805357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. System and facility readiness assessment for conducting active surveillance of adverse events following immunization in Addis Ababa, Ethiopia.
    Zeleke ED; Yimer G; Lisanework L; Chen RT; Huang WT; Wang SH; Bennett SD; Makonnen E
    Int Health; 2023 Nov; 15(6):676-683. PubMed ID: 36622733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Imprecision in vaccine adverse event reporting and a methodological analysis of reporting systems to improve pharmacovigilance and public health.
    Inokuma Y; Kneller R
    Eur J Clin Pharmacol; 2023 Jul; 79(7):989-1002. PubMed ID: 37249640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic review of reporting rates of adverse events following immunization: an international comparison of post-marketing surveillance programs with reference to China.
    Guo B; Page A; Wang H; Taylor R; McIntyre P
    Vaccine; 2013 Jan; 31(4):603-17. PubMed ID: 23200940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surveillance for adverse events following immunization (AEFI) for 7 years using a computerised vaccination system.
    Alguacil-Ramos AM; Muelas-Tirado J; Garrigues-Pelufo TM; Portero-Alonso A; Diez-Domingo J; Pastor-Villalba E; Lluch-Rodrigo JA
    Public Health; 2016 Jun; 135():66-74. PubMed ID: 26976484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pediatric anaphylactic adverse events following immunization in Victoria, Australia from 2007 to 2013.
    Cheng DR; Perrett KP; Choo S; Danchin M; Buttery JP; Crawford NW
    Vaccine; 2015 Mar; 33(13):1602-7. PubMed ID: 25698493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.